Your browser doesn't support javascript.
loading
The influence of adverse drug effects on health-related quality of life in chronic obstructive pulmonary disease patients.
Altawalbeh, Shoroq M; Almomani, Basima A; Alefan, Qais; Mohammad Momany, Suleiman; Al-Share, Qusai Y.
Afiliação
  • Altawalbeh SM; Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
  • Almomani BA; Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
  • Alefan Q; Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
  • Mohammad Momany S; Department of Internal Medicine, School of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
  • Al-Share QY; Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Int J Pharm Pract ; 30(5): 457-465, 2022 Nov 04.
Article em En | MEDLINE | ID: mdl-35849340
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Concerns have been raised about the influence of adverse drug effects on patient's health-related quality of life (HRQoL) in COPD patients. This study aimed to evaluate the impact of COPD treatment-related adverse effects on HRQoL in COPD patients. METHODS: In a cross-sectional study, COPD patients aged 40 years or older were identified and interviewed during their hospital visits. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire was used for evaluating HRQoL. Potential treatment adverse effects were evaluated as experienced by participants during the last 2 weeks preceding the interview. The intensity of adverse effects was reported in the following categories: never, mild, moderate and severe. Multivariable linear regression model was performed to evaluate the influence of adverse drug effects on utility scores as an indicator of HRQoL. KEY FINDINGS: A total of 203 patients diagnosed with COPD were recruited in the current study. The mean utility score of the study sample was 0.68 (SD = 0.36). Moderate-severe constipation, moderate-severe confusion, mild urinary hesitation, moderate-severe urinary hesitation, moderate-severe dry eyes and moderate-severe drowsiness were significant predictors/determinants for the average utility scores (coefficients were -0.099, -0.191, -0.111, -0.157 and -0.144, respectively). In addition, having higher COPD Assessment Test scores and severe disease was negatively associated with average utility scores (coefficients were -0.287 and -0.124, respectively). CONCLUSIONS: Higher intensity of COPD treatment-related adverse effects has a negative influence on HRQoL in COPD patients. Anticholinergic drug effects are of concern in COPD adults' population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Idioma: En Ano de publicação: 2022 Tipo de documento: Article